{
  "abstract": "We thank Dai et al for their constructive letter regarding our recent study defining preclinical stages of Crohn’s disease (CD) using faecal calprotectin in asymptomatic first-degree relatives (FDRs).1 We appreciate their recognition of the study’s contribution and welcome the opportunity to further contextualise our findings.",
  "authors": [
    {
      "affiliations": [
        "The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel",
        "Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel"
      ],
      "name": "Dan Turner"
    },
    {
      "affiliations": [
        "The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel"
      ],
      "name": "Sarah Kenigsberg"
    },
    {
      "affiliations": [
        "The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel"
      ],
      "name": "Gili Focht"
    },
    {
      "affiliations": [
        "Mount Sinai Hospital, Toronto, Ontario, Canada"
      ],
      "name": "Kenneth Croitoru"
    }
  ],
  "title": "Defining preclinical stages of Crohn’s disease by faecal calprotectin and other risk factors: response to letter",
  "uid": "25d3a45a-cdbe-59bc-b75a-48646d3810b1"
}